Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial. We did a phase 3, randomised, double-blind, placebo-controlled study in 90 centres in Australia, the Americas, Europe, and … (leggi tutto)

Studio randomizzato di fase 3 che dimostra come tivantinib, un inibitore selettivo di MET, non sia superiore in sopravvivenza globale rispetto a placebo in pazienti affetti da epatocarcinoma MET positivi pretrattati con sorafenib.